乌苯美司片配合GP方案化疗治疗晚期非小细胞肺癌的临床分析  

Clinical Analysis of Ubenimex Tablets Combined with GP Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer

作　　者：陈熙[1] 邓恋[1] CHEN Xi;DENG Lian(Second Department of Oncology,Nanxishan Hospital,Guangxi Zhuang Autonomous Region,Guilin,Guangxi Zhuang Autonomous Region,541002 China)

机构地区：[1]广西壮族自治区南溪山医院肿瘤二科,广西桂林541002

出　　处：《中外医疗》2021年第9期113-115,共3页China & Foreign Medical Treatment

摘　　要：目的比较乌苯美司片配合GP方案化疗治疗晚期非小细胞肺癌的效果。方法方便选取2019年7月—2020年7月间60例晚期非小细胞肺癌患者随机分为两组。治疗组:化疗同时加用乌苯美司片,对照组:单用化疗。观察两组的临床情况。结果治疗组有效率(CR+PR)为46.6%,临床受益率(CR+PR+NC)为86.7%,对照组有效率为40.0%,临床受益率为66.7%,两组临床受益率比较,差异无统计学意义(χ^(2)=3.354,P=0.067)。治疗后,对照组:CD3(45.9±2.2)%、CD4(26.2±2.2)%、CD8(26.5±2.1)%及CD4/CD8(0.98±1.09),治疗组:CD3(53.7±2.6)%、CD4(35.1±3.0)%、CD8(29.9±2.6)%及CD4/CD8(1.08±0.21),治疗组高于对照组,差异有统计学意义(P<0.05)。治疗组白细胞下降发生率为46.67%、血小板下降发生率为43.33%,对照组为白细胞下降发生率73.33%、血小板下降发生率70.00%,差异有统计学意义(χ^(2)=4.440、4.344,P<0.05)。非血液学毒性比较,治疗组胃肠道反应(腹胀、恶心、呕吐等)发生率为80.00%,对照组为83.33%,差异无统计学意义(χ^(2)=0.111,P>0.05)。其他不良反应如肝、肾功能损害、神经毒性、静脉炎等两组均较轻。结论乌苯美司片配合化疗治疗晚期非小细胞肺癌,可降低化疗对患者免疫功能的影响及不良反应。Objective To compare the effects of Ubenimex tablets combined with GP chemotherapy in the treatment of advanced non-small cell lung cancer.Methods Convenient to select from July 2019 to July 2020 sixty patients with advanced non-small cell lung cancer were randomly divided into two groups.Treatment group:chemotherapy plus Ubenimex tablets,control group:chemotherapy alone.Observe the clinical situation of the two groups.Results The effective rate(CR+PR)of the treatment group was 46.6%,the clinical benefit rate(CR+PR+NC)was 86.7%,the effective rate of the control group was 40.0%,and the clinical benefit rate was 66.7%.The clinical benefit rate of the two groups was 40.0%.In comparison,the difference was not statistically significant(χ^(2)=3.354,P=0.067).After treatment,the control group:CD3(45.9±2.2)%,CD4(26.2±2.2)%,CD8(26.5±2.1)%and CD4/CD8(0.98±1.09),treatment group:CD3(53.7±2.6)%,CD4(35.1±3.0)%,CD8(29.9±2.6)%and CD4/CD8(1.08±0.21),the treatment group was higher than the control group,and the difference was statistically significant(P<0.05).The incidence of leukopenia in the treatment group was 46.67%and the incidence of thrombocytopenia was 43.33%.In the control group,the incidence of leukopenia was 73.33%and the incidence of thrombocytopenia was 70.00%,and the difference was statistically significant(χ^(2)=4.440,4.344,P<0.05).In comparison of non-hematological toxicity,the incidence of gastrointestinal reactions(abdominal distension,nausea,vomiting,etc.)in the treatment group was 80.00%,and that in the control group was 83.33,and the difference was not statistically significant(χ^(2)=0.111,P>0.05).Other adverse reactions such as liver and kidney damage,neurotoxicity,and phlebitis were mild in the two groups.Conclusion Ubenimex tablets combined with chemotherapy in the treatment of advanced non-small cell lung cancer can reduce the effect of chemotherapy on the immune function and side effects of patients.

关 键 词：非小细胞肺癌 乌苯美司片 GP方案化疗 

分 类 号：R734.2[医药卫生—肿瘤]